U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07697339) titled 'HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma' on July 02.
Brief Summary: This is a Phase Ib/III, multicenter, open-label clinical study of HDM2005 in combination with rituximab and lenalidomide in adult patients with relapsed or refractory mantle cell lymphoma.
Mantle cell lymphoma is a type of non-Hodgkin lymphoma. Some patients have disease that comes back after treatment or does not respond well to available treatments. This study is designed to evaluate whether adding HDM2005 to rituximab and lenalidomide may provide clinical benefit for patients with relapsed or refractory mantle cell lymphoma who ha...